XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance.

doi:10.1158/0008-5472.CAN-24-3112

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance.

Cancer research - 2 Sept 2025

Totiger Tulasigeri M, Chiraphapphaiboon Wannasiri, Baca Yasmine, Chaudhry Sana, Notti Ryan Q, Montoya Skye, Chojnacka Monika, Gaidosh Gabriel, Afaghani Jumana, Affer Maurizio, Armstrong Christopher, Kavanaugh Paul M, Karaca Efe, Zabroski Jenna, Lewis Michael, Maye Alyssa, Jahn Jacob, Soni Rajesh K, Bilbao Daniel, Walker Phil, Elliott Andrew, Lou Emil, El-Deiry Wafik S, Rodriguez Jose Antonio, Nguyen Hai Dang, Taylor Justin

Abstract excerpt

Exportin-1 (XPO1) is a nuclear export receptor that is essential for cell survival. Previous genomic analyses have identified recurrent XPO1 hotspot mutations in cancer. In this study, we conducted a large-scale genomic analysis of 217,570 patients with cancer to identify and characterize XPO1 variants from real-world patient tumors. XPO1 harbored an R749Q mutation in various solid tumors, with a clear enrichment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exportin 1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrazines

Share to Karyopherins

Share to Poly-ADP-Ribose Binding Proteins

Share to Receptors, Cytoplasmic and Nuclear

Share to Topoisomerase I Inhibitors

Share to Triazoles

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40531821
DOI: 10.1158/0008-5472.CAN-24-3112
PMCID: PMC12354660

Genes

XPO1
POLE

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance.PMID 40531821Read ↗

Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesisSemantic proximity Read ↗

The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity Read ↗

Impact of Pan-Cancer Analysis of The Exportins Family on Prognosis, The Tumour Microenvironment and Its Potential Therapeutic EfficacySemantic proximity Read ↗

Targeting XPO1-Dependent Nuclear Export in Cancer.Semantic proximity Read ↗

Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.Semantic proximity Read ↗

Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian CancerSemantic proximity Read ↗

Identification and validation of a non-genetically encoded vulnerability to XPO1 inhibition in malignant rhabdoid tumors – expanding patient-driven discovery beyond the N-of-1Semantic proximity Read ↗

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Semantic proximity Read ↗

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.Semantic proximity Read ↗

Pan-Cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancerSemantic proximity Read ↗

XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.